Company / PP&E (Net)
Beam Therapeutics Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$104.5M
FY2025
5-year range
$84.3M / $125.0M
FY2021-FY2025
Trend
-6.2%
vs FY2024
Sector context
#45 of 193
Health Care
What the data says
Beam Therapeutics Inc.'s pp&e (net) of $105M is higher than 77% of companies in the Health Care sector (FY2025). Declined from $125M to $105M over the past 2 years.
Based on SEC 10-K filings.
$105M in FY2025 with a 5-year CAGR of +22.1%. Top quartile in the Health Care sector.
Declined from $125M to $105M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -3.3%
- 5-Year CAGR
- +22.1%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 193This company $104.5M Sector average $777.6M
▼
-86.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.1%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 6.2% year-over-year.
- Ranks #45 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $104.5M | -6.2% |
| FY2024 | $111.4M | -10.8% |
| FY2023 | $125.0M | +8.1% |
| FY2022 | $115.6M | +37.2% |
| FY2021 | $84.3M | +118.8% |
| FY2020 | $38.5M | +58.6% |
| FY2019 | $24.3M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026